PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Osteosarcoma is a cancerous (malignant) bone tumor that usually develops in teenagers. It occurs when a teen is growing rapidly.
Causes, incidence, and risk factors
Osteosarcoma is the most common bone cancer in children. Age at diagnosis is around 15. Boys and girls are just as likely to get this tumor until the late teen years, when it occurs more often in boys. Osteosarcoma is also common in people over age 60.
The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. This gene is also associated with familial retinoblastoma. This is a cancer of the eye that occurs in children.
Osteosarcoma tends to occur in the bones of the:
- Shin (near the knee)
- Thigh (near the knee)
- Upper arm (near the shoulder)
Osteosarcoma can occur in any bone. It occurs most commonly in large bones and in the area of bone with the fastest growth rate.
Symptoms
- Bone fracture (may occur after a routine movement)
- Limitation of motion
- Limping (if the tumor is in the leg)
- Pain when lifting (if the tumor is in the arm)
- Tenderness, swelling, or redness at the site of the tumor
Signs and tests
Treatment
Treatment usually starts after a biopsy of the tumor is done.
Before major surgery to remove the tumor, chemotherapy is usually given. This can shrink the tumor and make surgery easier. It also may kill any cancer cells that have spread to other parts of the body.
Chemotherapy medicines include:
- Carboplatin (Paraplatin)
- Cisplatin
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Epirubicin
- Ifosfamide (Ifex)
- Methotrexate (high dose) with leucovorin
Surgery is used after chemotherapy to remove any remaining tumor. In most cases, surgery can remove the tumor while saving the affected limb. This is called limb-salvage surgery. In rare cases, more involved surgery (such as amputation) is necessary.
Support Groups
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you and your family not feel alone.
Expectations (prognosis)
If the tumor has not spread to the lungs (pulmonary metastasis), long-term survival rates are better. If the cancer has spread to other parts of the body, the outlook is worse. However, there is still a chance of cure with effective treatment.
Complications
- Limb removal
- Spread of cancer to the lungs
- Side effects of chemotherapy
Calling your health care provider
Call your health care provider if you have persistent bone pain, tenderness, or swelling.
References
- GebhardtMA, Springfield D, Neff JR. Sarcomas of bone. In: Abeloff MD, Armitage JO, Niederhuber JE et al., eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, PA: Elsevier Churchill-Livingstone; 2008:chap96.
- Lerner A, Antman KH. Primary and metastatic malignant bone lesions. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 208.
- National Cancer Institute. PDQ Osteosarcoma and malignant fibrous histiocytoma or bone treatment. Bethesda, MD: National Cancer Institute. Date last modified 8/9/2012. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/osteosarcoma/HealthProfessional. Accessed November 16, 2012.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bone Cancer. Version 2.2012. Available at: http://www.nccn.org/professionals/physician_glspdf/bone.pdf. Accessed November 16, 2012.
Review Date: 11/17/2012.
Reviewed by: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, David R. Eltz, Stephanie Slon, and Nissi Wang.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Drugs to prevent hearing loss in children receiving platinum chemotherapy for cancer
Platinum‐based chemotherapy, including cisplatin, carboplatin and/or oxaliplatin, is used in the treatment of different types of childhood cancer. Unfortunately, one of the most important adverse effects of platinum chemotherapy is hearing loss. This can occur not only during treatment but also years after the end of treatment. Although hearing loss is not life‐threatening the loss of hearing, especially during the first three years of life, may lead to difficulties with school performance and psychosocial functioning. Prevention of platinum‐induced hearing loss is thus very important and might improve the quality of life of childhood cancer patients and survivors treated with platinum‐based chemotherapy.
Tips for reading the newsDon’t automatically believe the headlines. Learn how to figure out which articles you’re going to believe and which you’re not.
- OsteosarcomaOsteosarcomaPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...


